"The next few quarters may certainly be very good for pharma companies. But these are no longer the secular growth stories which we have pursued back in the 2000 or 2010 era, when companies like Sun Pharma, Lupin, Dr. Reddy, Cipla were easily growing at 20% plus," says Dipan Mehta.